Myriad receives FDA approval of BRACAnalysis CDX® as companion diagnostic for Lynparza™ (olaparib)
New treatment for patients who have BRCA1/2 mutations and HER2-negative metastatic breast cancer
NCCN Clinical Guideline updates increase genetic testing access for patients with metastatic breast and prostate cancers
Revisions drive optimized treatment for patients & answers for family members
Laboratory QA process drives clinical utility of hereditary cancer testing
Recent publication shows how comprehensive quality assurance processes curtail unnecessary healthcare costs while driving clinical utility of testing
ACOG & SGO release joint statement on Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
The American College of Obstetricians and Gynecologists (ACOG) and Society of Gynecologic Oncology
Findings from SOLO2/ENGOT-Ov21 confirm efficacy of PARP inhibitor in patients with BRCA-mutated ovarian cancer
Results from trial published in Lancet Oncology
ASCO Annual Meeting delivers data showing hereditary cancer testing benefit
June 2017 | Issue 2
Presentations highlight critical results for patients managing cancer
Medicare Expands Coverage of Prolaris®
June 2017 | Issue 1
Medicare has announced expanded coverage of Prolaris, a prostate cancer prognostic biomarker test. Now Medicare patients with NCCN favorable intermediate-risk disease have coverage, in addition to very low- and low-risk patients (MolDX LCD IDs: L36350 and L37082).
Publication demonstrates significant discordance in genetic variant classifications found in public database compared to a commercial laboratory
May 2017 | Issue 2
An article published in The Oncologist in April, 2017 explores discordance among variant classifications housed in public databases when compared to a commercial testing laboratory.
Recent data demonstrate benefit of PARP inhibitors for patients with ovarian cancer
May 2017 | Issue 1
The promise of precision medicine is realized when medical care is optimized to serve the right patient at the right time with the right treatment or therapy.
Myriad announces the launch of EndoPredict®, a gene expression test for patients with breast cancer
EndoPredict provides a patient’s 10-year risk of distant recurrence. This information can be used to determine if a patient can forgo adjuvant chemotherapy. Published literature demonstrates EndoPredict’s greater prognostic value compared to first generation tests.
Applying the Center for Medical Technology Policy’s (CMTP) chain of evidence for clinical utility to Prolaris, a prognostic prostate cancer test developed by Myriad Genetic Laboratories
Genomic medicine has opened promising avenues for molecular diagnostic testing in health care.
Blue Cross Blue Shield Association drives progress for patients with breast cancer
Evidence Street™ has recently announced that EndoPredict® results in a meaningful improvement in the net health outcomes in node-negative breast cancer patients.